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Narcolepsy affects around 4 in 10 000 people, making it about
one quarter as common as multiple sclerosis in the United
Kingdom.1 Its cardinal features are excessive daytime sleepiness
causing frequent, irresistible naps; cataplexy, leading to collapse,
embarrassment, and sometimes injury; and marked disturbance
of nocturnal sleep. It is usually due to a specific deficiency of
the hypothalamic neurotransmitter hypocretin and most often
starts in the teens, probably as the result of an autoimmune
process. Narcolepsy is far more than an occasional dose of
sleepiness: it is a lifelong, pervasive, and potentially disabling
disorder with a similar effect on quality of life to treatment
resistant epilepsy.2
While potentially disabling, it is also highly treatable.3 A
combination of stimulants (typicallymodafinil or dexamfetamine
or both) and antidepressants (to reduce cataplexy) improves
symptoms appreciably in most patients. But treatment response
may be partial; contraindications or side effects can prevent
their use; and none of these drugs deals with the third cardinal
symptom of narcolepsy, which is sometimes the most
distressing—the fragmentation of nocturnal sleep.
Enter sodium oxybate (Xyrem) or γ-hydroxybutyrate (GHB),
an agonist at GABAB (γ-aminobutyric acid type B) and GHB
receptors.4 It has a chequered history. Following a period of use
as a hypnotic and anaesthetic, GHB acquired a louche reputation
as a date rape and recreational drug. More recently a series of
trials have shown its efficacy in treating narcolepsy: given at
night in two doses 3-4 hours apart, sodium oxybate consolidates
nocturnal sleep, reduces excessive daytime sleepiness, and often
abolishes cataplexy. Its potential to cause respiratory depression
in overdose and substantial sedation at therapeutic doses, with
attendant risks of falls in the night, enuresis, and new onset
parasomnias, means that a careful approach to prescribing is
needed, especially in patients with compromised respiration in
sleep because of, for example, obstructive sleep apnoea.
However, it is the only drug available for use in narcolepsy that
simultaneously treats all three cardinal symptoms. Since it was
licensed in 2006, we, in common with sleep specialists around
the world, have found it a remarkably effective treatment.
Despite the need for gradual titration and the nuisance of taking
the drug twice nightly, many patients find sodium oxybate life
transforming, often enabling them to return to work or to study
after months or years of enforced absence.
Sodium oxybate is currently priced at around £13 000 (€16 764;
$18 929) a year at full dose, although many patients are
optimally treated on lower doses. Prescribing policies around
the UK are inconsistent. The Department of Health has agreed
to underwrite its cost in selected vaccine related cases (a small
narcolepsy epidemic followed the use of Pandemrix, a brand of
H1N1 flu vaccine, in 2009-10).5 Some clinical commissioning
groups have agreed sensible prescribing arrangements with local
hospitals—for example in Cambridgeshire,6 London, and
Merseyside. In most parts of the country, however, use of the
drug requires the approval of an individual funding request,
showing that a patient’s need is “exceptional.”7 8
This process is tortuous, primarily because of the lack of clarity
in the definition of exceptionality. Given the drug’s cost,
together with variations in the severity of narcolepsy and
response to standard treatments, prescribing policies that restrict
its use to more severely affected patients who respond poorly
to other treatment seem sensible. But under the opaque operation
of the exceptionality rule, a patient will be allowed sodium
oxybate only if his or her response to the drug is judged likely
to be exceptional compared with that of a patient with a similar
degree of clinical need. This cannot be predicted from the
available trial data. In our joint experience of around 30
applications, the increasingly rare agreements to fund the drug
are emerging at random. Of 10 recent applications made by the
authors in carefully selected patients, none has been successful.
Reasons given for refusal have included the explanation that
“the patient belongs to a cohort of similar patients.” This
logically necessary truth provides a convenient but empty
justification for declining to fund valuable therapies.
Sodium oxybate is costly, potent, and should be prescribed with
care. However, the individual funding request process is time
wasting for doctors, frustrating for patients, and fundamentally
irrational. It should be abandoned. We suggest that it should be
replaced by agreements, like those mentioned above, to fund
the drug, under the care of appropriate specialists, for patients
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whomeet predetermined criteria, including more severe disease
or failure of, contraindications to, or serious side effects from
other treatments.We note that NHS England has recently issued
a draft proposal relating to the use of sodium oxybate in
postpubertal children9 along lines similar to these; we welcome
this but can see no good reason for adopting different policies
towards postpubertal children and adults. We hope that the
recent decision to allow a judicial review of prescribing10 will
lead to a more rational and equitable approach to the use of this
expensive but valuable drug that is allowing many people with
narcolepsy to maintain their personal and social relationships,
achieve their academic potential, and remain in employment.
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